PEGylated Nanoemulsions Containing 1,2-Distearoyl-sn-Glycero-3-Phosphoglycerol Induced Weakened Accelerated Blood Clearance Phenomenon

Zhe Li, Xin Gao, Xinyang Yan, Yuihui Deng, Haiying MaResearch 2021 · DOI

Abstract

Injections of polyethylene glycol (PEG)-modified nanomedicines can lead to an accelerated clearance of the next dose of PEGylated nanomedicines, which is referred to as the accelerated blood clearance (ABC) phenomenon. It has been reported that anti-PEG IgM plays an important role in the induction of the ABC phenomenon, identifying the interface between the main chain of PEG and the hydrophobic segment of the repeated injections of the PEGylated nanocarriers, resulting in increased liver uptake and loss of long cycle characteristics. In this study, we demonstrated that the 1,2-distearoyl-sn-glycero-3-phosphoglycerol (DSPG) in PEGylated nanoemulsions (PEs) may mask this interface between the main chain of PEG and the hydrophobic segment, inhibiting the recognition and binding of anti-PEG IgM to PEs, and evidently weakening the ABC phenomenon of PEs. This will provide a novel strategy to improve the curative effect of PEGylated nanocarriers.

Introduction

Polyethylene glycol (PEG) is widely considered the "gold standard" for enhancing the "stealth" properties of nanomedicines. By coating drug carriers in PEG (PEGylation), researchers can improve solubility and extend circulation time in the bloodstream. However, a significant hurdle exists: the Accelerated Blood Clearance (ABC) phenomenon. Upon initial exposure to a PEGylated carrier, the immune system often produces anti-PEG IgM antibodies. When a subsequent dose is administered, these antibodies recognize the interface where the PEG chain meets the hydrophobic interior of the carrier, triggering rapid clearance by the liver and spleen. This study investigates how incorporating 1,2-distearoyl-sn-glycero-3-phosphoglycerol (DSPG) into PEGylated nanoemulsions (PEs) can mask this interface and mitigate the ABC effect.

Materials and Methods

The researchers developed PEGylated nanoemulsions (PEs) using soybean phosphatidylcholine (S75) and mPEG2000-DSPE. To test the masking hypothesis, varying concentrations of DSPG were introduced into the formulations.

Table 1: Lipid compositions of the PEGylated nanoemulsions (PEs) and DSPG-modified PEs.

Pharmacokinetic studies were conducted in male Wistar rats ($n=3$ per group). The experimental design involved two intravenous injections spaced seven days apart to observe the induction and effect of the ABC phenomenon.

Table 2: Experimental dosing groups for single and repeated administration studies.

Fluorescence tracking (DiR marker) and ELISA were used to monitor blood concentrations and anti-PEG IgM levels, respectively. Co-injection studies were also performed to determine if DSPG must be integrated into the particle surface or simply present in the circulation.

Results and Discussion

Structural Masking of the PEG-Lipid Interface

Previous research indicates that anti-PEG antibodies target the amide bond junction between the hydrophilic PEG and the hydrophobic lipid anchor (DSPE). DSPG, which possesses a similar fatty acid chain but features two free hydroxyl groups, was hypothesized to provide a physical or electrostatic shield over this junction.

Abolishing the ABC Phenomenon

The study found that standard PEGylated emulsions exhibited a severe ABC effect, with an $ABC_{index}$ of approximately 0.14 for the second dose. However, the addition of DSPG significantly improved circulation. At a molar ratio of 30:1 (DSPG to PEG), the $ABC_{index}$ reached 0.94, indicating that the second dose remained in circulation nearly as long as the first. This modification successfully bypassed the massive liver and spleen accumulation typically seen in ABC-positive subjects.

Mechanism of Action

Interestingly, the presence of DSPG did not prevent the production of anti-PEG IgM antibodies. Instead, it inhibited the antibodies from binding to the nanoemulsions. This suggests that DSPG changes the "lock" (the emulsion surface) so that the "key" (the antibody) can no longer recognize its target. Crucially, co-injecting free DSPG did not stop the ABC phenomenon; the phospholipid must be integrated into the emulsion's surface to be effective.

Conclusion

Integrating DSPG into PEGylated nanoemulsions offers a promising strategy to overcome the ABC phenomenon. By masking the critical chemical interface recognized by the immune system, DSPG-modified carriers maintain their long-circulation properties even after repeated dosing. While these results in Wistar rats are encouraging, further research is needed to validate this approach in humans and across different types of nanocarriers, such as liposomes or polymeric nanoparticles.

Reference: Li, Z., Gao, X., Yan, X. et al. PEGylated Nanoemulsions Containing 1,2-Distearoyl-sn-Glycero-3-Phosphoglycerol Induced Weakened Accelerated Blood Clearance Phenomenon. Drug Delivery and Translational Research (2022). DOI: 10.1007/s13346-021-01111-4

Summary updated

Abstract

Abstract Injections of polyethylene glycol (PEG)-modified nanomedicines can lead to an accelerated clearance of the next dose of PEGylated nanomedicines, which is referred to as the accelerated blood clearance (ABC) phenomenon. It has been reported that anti-PEG IgM plays an important role in the induction of the ABC phenomenon, identifying the interface between the main chain of PEG and the hydrophobic segment of the repeated injections of the PEGylated nanocarriers, resulting in increased liver uptake and loss of long cycle characteristics. In this study, we demonstrated that the 1,2-distearoyl-sn-glycero-3-phosphoglycerol (DSPG) in PEGylated nanoemulsions (PEs) may mask this interface between the main chain of PEG and the hydrophobic segment, inhibiting the recognition and binding of anti-PEG IgM to PEs, and evidently weakening the ABC phenomenon of PEs. This will provide a novel strategy to improve the curative effect of PEGylated nanocarriers.
BibTeX
@inproceedings{li2021pegylated,
  author = {Zhe Li and Xin Gao and Xinyang Yan and Yuihui Deng and Haiying Ma},
  title = {{PEGylated Nanoemulsions Containing 1,2-Distearoyl-sn-Glycero-3-Phosphoglycerol Induced Weakened Accelerated Blood Clearance Phenomenon}},
  booktitle = {Research},
  year = {2021},
  doi = {10.21203/rs.3.rs-911131/v1},
}
Figure